Page last updated: 2024-08-21

pyrazines and desipramine

pyrazines has been researched along with desipramine in 3 studies

Research

Studies (3)

Timeframe	Studies, this research(%)	All Research%
pre-1990	1 (33.33)	18.7374
1990's	1 (33.33)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (33.33)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Clineschmidt, BV; McGuffin, JC; Pflueger, AB; Totaro, JA	1
Battaglia, G; Brownfield, MS; Cabrera, TM; Levy, AD; Li, Q; Rittenhouse, PA; van de Kar, LD	1
Chandler, J; Decker, R; Hynes, SM; Mitchell, M; Ott, J; Wickremsinhe, E; Zhang, W	1

Trials

1 trial(s) available for pyrazines and desipramine

Article	Year
Evaluation of the likelihood of a selective CHK1 inhibitor (LY2603618) to inhibit CYP2D6 with desipramine as a probe substrate in cancer patients. Biopharmaceutics & drug disposition, 2015, Volume: 36, Issue:1 Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Area Under Curve; Checkpoint Kinase 1; Computer Simulation; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP2D6 Inhibitors; Desipramine; Drug Interactions; Female; Humans; Infusions, Intravenous; Least-Squares Analysis; Male; Middle Aged; Neoplasms; Phenylurea Compounds; Protein Kinases; Pyrazines; Young Adult	2015

Article

Year

Evaluation of the likelihood of a selective CHK1 inhibitor (LY2603618) to inhibit CYP2D6 with desipramine as a probe substrate in cancer patients.

Biopharmaceutics & drug disposition, 2015, Volume: 36, Issue:1

Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Area Under Curve; Checkpoint Kinase 1; Computer Simulation; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP2D6 Inhibitors; Desipramine; Drug Interactions; Female; Humans; Infusions, Intravenous; Least-Squares Analysis; Male; Middle Aged; Neoplasms; Phenylurea Compounds; Protein Kinases; Pyrazines; Young Adult

2015

Other Studies

2 other study(ies) available for pyrazines and desipramine

Article	Year
Inhibition of the serotoninergic uptake system by MK-212 (6-chloro-2-[1-piperazinyl]-pyrazine) Pharmacological research communications, 1978, Volume: 10, Issue:3 Topics: Animals; Cerebral Cortex; Clomipramine; Depression, Chemical; Desipramine; Dopamine; Female; In Vitro Techniques; Neurons; Norepinephrine; p-Chloroamphetamine; Piperazines; Pyrazines; Rats; Serotonin	1978
Long-term treatment with the antidepressants fluoxetine and desipramine potentiates endocrine responses to the serotonin agonists 6-chloro-2-[1-piperazinyl]-pyrazine (MK-212) and (+-)-1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane HCl (DOI). The Journal of pharmacology and experimental therapeutics, 1993, Volume: 266, Issue:2 Topics: Adrenocorticotropic Hormone; Amphetamines; Animals; Desipramine; Drug Synergism; Fluoxetine; Hormones; Ketanserin; Male; Pyrazines; Rats; Rats, Sprague-Dawley; Serotonin Receptor Agonists; Vasopressins	1993

Article

Year

Inhibition of the serotoninergic uptake system by MK-212 (6-chloro-2-[1-piperazinyl]-pyrazine)

Pharmacological research communications, 1978, Volume: 10, Issue:3

Topics: Animals; Cerebral Cortex; Clomipramine; Depression, Chemical; Desipramine; Dopamine; Female; In Vitro Techniques; Neurons; Norepinephrine; p-Chloroamphetamine; Piperazines; Pyrazines; Rats; Serotonin

1978

Long-term treatment with the antidepressants fluoxetine and desipramine potentiates endocrine responses to the serotonin agonists 6-chloro-2-[1-piperazinyl]-pyrazine (MK-212) and (+-)-1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane HCl (DOI).

The Journal of pharmacology and experimental therapeutics, 1993, Volume: 266, Issue:2

Topics: Adrenocorticotropic Hormone; Amphetamines; Animals; Desipramine; Drug Synergism; Fluoxetine; Hormones; Ketanserin; Male; Pyrazines; Rats; Rats, Sprague-Dawley; Serotonin Receptor Agonists; Vasopressins

1993